Locally advanced cervical cancer
Conditions
Interventions
Two groups:neoadjuvant chemotherapy combined with surgical treatment versus concurrent chemoradiotherapy
Sponsors
Renming Hospital of Three Gorges University & The First People's Hospital of Yichang
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. patients aged 18 to 70 years old; 2. 2009 FIGO clinical staging IB2, IIA2 stage cervical cancer; 3. Eastern Cooperative Oncology Group performance status score < 2; 4. the initial treatment of patients; 5. MRI showed that the tumors in cervical; 6. Patients who are not pregnant and not in lactation; 7. signed informed consent. ;Inclusion criteria: 1. patients aged 18 to 70 years old; 2. 2009 FIGO clinical staging IB2, IIA2 stage cervical cancer; 3. Eastern Cooperative Oncology Group performance status score < 2; 4. the initial treatment of patients; 5. MRI showed that the tumors in cervical; 6. Patients who are not pregnant and not in lactation; 7. signed informed consent.
Exclusion criteria
Exclusion criteria: 1. patients with overt infection; 2. has serious complications, such as heart disease, uncontrolled diabetes, hypertension, bleeding tendency; 3. The patient had previously been treated for cervical cancer; 4. In the first 30 days of the trial, the patient took other antineoplastic drugs; 5. Patients who are receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy; 6. pregnant or breast-feeding women; 7. with other concomitant malignant tumors, orsuffered from other malignant tumors nearly 5 years. ;Exclusion criteria: 1. patients with overt infection; 2. has serious complications, such as heart disease, uncontrolled diabetes, hypertension, bleeding tendency; 3. The patient had previously been treated for cervical cancer; 4. In the first 30 days of the trial, the patient took other antineoplastic drugs; 5. Patients who are receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy; 6. pregnant or breast-feeding women; 7. with other concomitant malignant tumors, orsuffered from other malignant tumors nearly 5 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life;Adverse reaction;;Quality of life;Adverse reaction; | — |
Contacts
Public ContactManZhen Zuo;ManZhen Zuo ;
Renming Hospital of Three Gorges University & The First People's Hospital of Yichang;Renming Hospital of Three Gorges University & The First People's Hospital of Yichang
Outcome results
None listed